Αποτελέσματα Αναζήτησης
14 Μαΐ 2019 · Development of one or more herpes simplex virus (HSV) vaccines is an important objective for sexual and reproductive health worldwide. WHO preferred product... Download. Read More. Roadmap. Vaccines against sexually transmitted infections (STIs) are a major priority for sustainable global STI control.
Moderna is developing a vaccine using mRNA technology to treat the herpes simplex virus (HSV). There are two HSV virus types — HSV-1, the one I have, that affects the mouth, face and genitals...
21 Δεκ 2022 · Dec 21 (Reuters) - BioNtech (22UAy.DE) has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical...
5 Μαρ 2024 · GlaxoSmithKline plc. (GSK), known for its extensive range of vaccines for various conditions, including RSV, meningitis, and shingles, is conducting an innovative study to evaluate the safety, immune response, efficacy, and reactogenicity of HSV-targeted immunotherapy (HSVTI).
29 Μαρ 2023 · This update is essential, as there are no FDA-approved herpes vaccines available. However, there are two mRNA-based vaccine candidates. HSV treatments and preventive vaccines are in great demand.
Shingrix is a vaccine used in adults aged 50 years and over to protect against shingles (herpes zoster) and post-herpetic neuralgia (long-lasting nerve pain following shingles). It can also be used from the age of 18 years and over in adults who are at increased risk of herpes zoster.
21 Δεκ 2022 · First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163. BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter the clinic.
